Literature DB >> 35178166

Factor XI Activation Inhibitors for Treating Thrombosis, Embolisms, Hypercoagulability, and Fibrotic Changes.

Ram W Sabnis1.   

Abstract

Entities:  

Year:  2022        PMID： 35178166      PMCID： PMC8842103          DOI： 10.1021/acsmedchemlett.1c00724

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.345


× No keyword cloud information.
  6 in total

Review 1.  Translational insight into prothrombotic state and hypercoagulation in nonalcoholic fatty liver disease.

Authors:  Alessandro Ciavarella; Davide Gnocchi; Carlo Custodero; Gennaro Mariano Lenato; Giorgio Fiore; Carlo Sabbà; Antonio Mazzocca
Journal:  Thromb Res       Date:  2020-12-11       Impact factor: 3.944

Review 2.  Factor XI Deficiency.

Authors:  Magdalena Dorota Lewandowska; Jean Marie Connors
Journal:  Hematol Oncol Clin North Am       Date:  2021-09-15       Impact factor: 3.722

Review 3.  The Function of extravascular coagulation factor IX in haemostasis.

Authors:  David M Mann; Katherine A Stafford; Man-Chiu Poon; Davide Matino; Darrel W Stafford
Journal:  Haemophilia       Date:  2021-03-29       Impact factor: 4.287

Review 4.  Anticoagulation in patients with kidney failure on dialysis: factor XI as a therapeutic target.

Authors:  John Eikelboom; Jürgen Floege; Ravi Thadhani; Jeffrey I Weitz; Wolfgang C Winkelmayer
Journal:  Kidney Int       Date:  2021-09-30       Impact factor: 10.612

Review 5.  Dual inhibition of factor XIIa and factor XIa as a therapeutic approach for safe thromboprotection.

Authors:  Stéphanie Demoulin; Edmond Godfroid; Cédric Hermans
Journal:  J Thromb Haemost       Date:  2020-12-10       Impact factor: 5.824

Review 6.  Factor XI Inhibition to Uncouple Thrombosis From Hemostasis: JACC Review Topic of the Week.

Authors:  Charles Hsu; Edward Hutt; Daniel M Bloomfield; David Gailani; Jeffrey I Weitz
Journal:  J Am Coll Cardiol       Date:  2021-08-10       Impact factor: 27.203
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.